Cell and Gene Therapy Manufacturing Market Share, Size, Industry Analysis, Growth, Trends, Emerging Technologies, Recent Developments and Forecast 2023 to 2033

BySanket Badgujar
Market Research

The global Cell And Gene Therapy Manufacturing Market is anticipated to create phenomenal growth opportunities over the forecast period by registering a CAGR of 29% from 2023 to 2033. The global market reached a valuation of around US$ 15.6 Billion in 2022 and is expected to surpass a valuation of around US$ 240 Billion by 2033. As per the Cell and Gene Therapy Manufacturing Market research by Future Market Insights – a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value increased at around 22% CAGR.

Market revenue through Cell Therapy Manufacturing is expected to be the highest revenue-generating segment, accounting for an expected CAGR of 31.8% from 2023 to 2033. The augmenting frequency of cancer and other target diseases, combined with increasing research and development spending in pharmaceutical companies, are driving market expansion.

Get a PDF Sample with Latest Market Insights@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16515

Immunotherapy, gene transfer, and oncolytic virotherapy are three separate gene therapy treatments that are excessively utilized to treat cancer. As the number of instances increases, so will the reliance on gene therapy, thus driving the market growth. In addition to that, it has been estimated that more than 50 million people will be diagnosed with cancer within the next five years.

Report Highlights:

Breast cancer has significantly suppressed lung cancer, by being one of the most commonly diagnosed cancers worldwide. For the first time, owing to its high incidence in low- and middle-income nations. Because cancer is one of the most complex diseases, cell and gene therapy is one of the fields with a significant opportunity for cancer treatment.

Aging populations and socioeconomic risk factors are two of the most common causes of cancer cases worldwide. Breast cancer is also one of every four cancers diagnosed in women worldwide, according to the same source.

GLOBOCAN 2020 has been revised by the International Agency for Research on Cancer (IARC), which reveals that the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020.

Recent Developments:

There are approximately 1,200 cell and gene therapies in clinical trials worldwide. In the USA alone, there are around 700 investigational cell and gene therapies in clinical trials.

Various manufacturing facilities are unable to keep up with global requirements. Hundreds of more facilities are expected to be required to manufacture the therapies currently in clinical development. Viral capacity is one of the areas that has to be accelerated.

A significant portion of the viral vectors is built with adherent manufacturing, which is expensive to run. A vial of 20 million cells are likely to cost anywhere between US$ 20,000 and US$ 30,000 to generate. The cost of producing gene therapy can range from US$ 500,000 to US$ 1 million, excluding research and development, clinical trial costs, and the costs of establishing the commercial infrastructure required to offer access to patients.

Competitive Landscape:

The surging interest of key public and private investors in the development of advanced therapies are expected to boost market revenue during the forecast period. In addition, key firms are enhancing their market presence through strategic activities such as mergers and acquisitions, licensing, and partnerships.

More Insights into the Cell and Gene Therapy Manufacturing Market:

The North American region is anticipated to dominate the global cell and gene therapy manufacturing market over the forecast period. The U.S.A. accounted for a massive proportion of the market revenues in 2022. The key driving factors for the market expansion in the country are the large number of active clinical trials, as well as the growing engagement of firms in gene and cell therapy research and development. With more than 400 businesses actively engaged in the development of cell and gene therapy products for various diseases, North America was ranked top for having the most gene therapy clinical trials.

The United Kingdom market is expected to showcase a positive growth outlook over the evaluation period. The European region is expected to reach a valuation of US$ 6.5 Billion by 2033. Growing with a CAGR of 23.9% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 5.7 Billion.

In countries like Japan, the global market is expected to propel at a CAGR of 32.5% from 2023 to 2033, surpassing a valuation of US$ 12.6 Billion by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 11.9 Billion during the forecast period.

Key Companies Profiled:

  • Thermo Fisher Scientific
  • Merck KGaA
  • Lonza
  • Catalent Inc.
  • Takara Bio Inc.
  • F. Hoffmann-La Roche Ltd
  • Wuxi Advanced Therapies
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novartis AG
  • Hitachi Chemical Co., Ltd.
  • Cellular Therapeutics
  • Miltenyi Biotec
  • Bluebird Bio Inc.

Market Segments Covered in Cell and Gene Therapy Manufacturing Market Analysis:

By Therapy Type:

  • Cell Therapy Manufacturing
    • Stem Cell Therapy
    • Non-Stem Cell Therapy
  • Gene Therapy Manufacturing

By Scale:

  • Pre-commercial/ R&D Manufacturing
  • Commercial Scale Manufacturing

By Mode:

  • Contract Manufacturing
  • In-house Manufacturing

By Workflow:

  • Cell Processing
  • Cell Banking
  • Process Development
  • Fill & Finish Operations
  • Analytical And Quality Testing
  • Raw Material Testing
  • Vector Production
  • Other Workflows

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa